BCAL Commences US Operations

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”) is pleased to announce that it has established a North Carolina, United States of America, incorporated wholly owned subsidiary, BCAL Diagnostics, Inc. (“BCAL US”) which will commence operations on 2 September 2024.

Highlights:

• Establishment of BCAL US subsidiary
• Dr. Klaus-Peter Adam joins BCAL as Director US Research and Product Development
• Lease of US premises secured and key equipment purchased
• BCAL US research laboratory to commence operations 2 September 2024

The opportunity to establish BCAL US and commence operations arose out of BCAL research partner Precion Inc undertaking an internal restructure. Key features are:

• BCAL US being established as a wholly owned subsidiary of BCAL, with BCAL US officeholders being Shane Ryan as President and BCAL directors Jayne Shaw, Dr. John Hurrell and Jonathan Trollip as directors of BCAL US.
• The purchase from Precion Inc. of equipment is required for the functioning of a US laboratory.
• The former Chief Technology Officer of Precion, Dr. Klaus-Peter Adam, will join BCAL US, as full-time Director of US Research and Product Development and will oversee BCAL US operations.
• The BCAL US strategy is quickly building momentum. Dr. Adam is a highly credentialled scientist, specializing in the area of metabolomics and lipidomics who will bring much needed expertise to our growing US team and enhance our global research team. The US program offers BCAL an opportunity to accelerate and validate new products on US patient centric data and gain an in-county understanding of the US diagnostics market. Collaboration with US Physicians is progressing at the first partner two sites, Michigan and Chicago. Dr. John Hurrell (BCAL Board member and Consultant) is based in the US and brings strong industry relevant expertise of the US market, having held senior leadership roles in the US diagnostics space, including Quest Diagnostics. BCAL is also pleased to announce the appointment of MS Cory Dunn who brings a wealth of US and Australian marketing experience and comprehensive knowledge of the US breast cancer network.

While the specific financial terms on which BCAL has been able to establish its US operations are commercially confidential, the BCAL board considers the opportunistic establishment of BCAL US as being extremely cost-effective. Additionally, as result of the recent $10.5 million capital raising, BCAL US has been established and can operate over the short-term without needing to raise any further capital.

Click here for the full ASX Release

This article includes content from Bcal Diagnostics Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.